Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

318

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-alcoholic Steatohepatitis
Fibrosis
Liver Diseases

Interventions

DRUG: Emricasan (5 mg)
DRUG: Emricasan (50 mg)
DRUG: Placebo

Sponsor

Conatus Pharmaceuticals Inc.